News & Events

News


Tuesday July 10, 2018

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results

Conference Call and Webcast Scheduled for Tuesday, July 31 SAN DIEGO, July 10, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Tuesday, July 31, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9177 (US) or 785-424-1669 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine's website under Inves...


Friday June 08, 2018

Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego

SAN DIEGO, June 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is proud to announce that Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences, received the Entrepreneur Of The Year® 2018 Award in the Life Sciences category in San Diego . The EY awards program recognizes entrepreneurs whose ingenuity, spirit of innovation and discipline have driven their companies' success, transformed their industries and made a positive impact on their communities. Dr. Gorman was selected by an independent panel of judges, and the awar...


Wednesday May 09, 2018

Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference

Live Audio Webcast Will be on May 15, 2018 SAN DIEGO, May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 15, 2018, in Las Vegas, Nevada. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. About Neurocrine Biosciences, Inc. N...


Tuesday May 08, 2018

Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics

- Nearly 28 Percent of Patients Treated with Antipsychotics in the RE-KINECT Study Had Clinician-Confirmed Possible Tardive Dyskinesia - Over Half of Patients with Possible Tardive Dyskinesia Experienced Uncontrollable Movements in Two or More Body Regions - New Data from KINECT 4 Study Show Long-Term Treatment with INGREZZA® (valbenazine) Capsules Provided Sustained, Clinically Meaningful Improvement in Tardive Dyskinesia and was Well-Tolerated SAN DIEGO, May 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), p...


Wednesday May 02, 2018

Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting

New Data Provide Insight Into the Real-World Impact of Potential Tardive Dyskinesia in Patients Treated With Antipsychotic Medicines New Data From KINECT 4 Study Describe the Results of Long-Term INGREZZA® (valbenazine) Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder SAN DIEGO, May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated w...

Events